Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A randomized controlled trial has questioned the widespread use of the α-blocker alfuzosin as an empirical treatment for chronic prostatitis–chronic pelvic pain syndrome. Instead, only a small subgroup of patients might benefit from this therapy.
The growth of prostate acini from single cell implants in mice is a major breakthrough. Such results have important clinical implications, and will ultimately change the treatment paradigm for prostatic disease.
Data on the value of dietary supplements in reducing the risk of developing prostate cancer have been conflicting; however, two large randomized trials have indicated that prostate cancer risk is not reduced by the long-term use of vitamin E, vitamin C or selenium supplements.
Increasing the number of prostate biopsy cores taken does not improve diagnostic accuracy. Instead, urologists need to think in three dimensions and use template guidance to improve cancer detection and characterization.
For patients who present with localized prostate cancer, focal therapy could be a treatment option; however, accurate imaging of the prostate is required for focal therapy to be viable. This Review by Turkbey et al. discusses the conventional methods for imaging the prostate, the new developments for targeted imaging, and the possible role of image-guided biopsy and focal therapy.
The selection of patients with prostate cancer who are suitable for focal therapy remains a controversial topic. In this Review, Mouraviev and colleagues discuss pathological insights into the biology of early-stage disease, and highlight the critical role of three-dimensional prostate mapping protocols in the localization of disease.
Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, but no drugs for FSAD have been approved. In this Review, Schoen and Bachmann discuss the use of sildenafil citrate, a phosphodiesterase type-5 inhibitor, for FSAD treatment. They provide the rationale for treatment, and discuss results of sildenafil citrate from past clinical studies in women with FSAD.
This Case Study describes a 48-year-old man who was referred to a specialist oncology center for management of presumed angiosarcoma. Further investigation revealed high-risk penile epithelioid hemangioendothelioma. This article highlights the spectrum of clinical behavior of this atypical epithelioid vascular tumor, and provides possible treatment options for low-risk and high-risk forms of this cancer.
Many patients with urologic disorders, particularly cancer, use complementary therapies as adjuncts to mainstream treatment. Accumulating evidence highlights the beneficial impact of supportive measures, such as acupuncture, yoga, meditation and physical activity, on the symptoms of patients with urologic disorders. These data, as well as studies of herbs and other dietary supplements, are discussed here.
